The Integration of ADCs: Understanding
The Advancing Treatment of PROC,
an Industry Supported Symposium at ESGO 2024

Activity Overview

The GOG Foundation, Inc., GOG Partners and ImmunoGen, Inc., welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to register for the The Integration of ADCs: Understanding The Advancing Treatment of PROC, an Industry Supported Symposium at the ESGO 2024 Congress in Barcelona, Spain.

The current competitive landscape in platinum resistant ovarian cancer (PROC) is rapidly evolving.  In this course, expert faculty will outline the unmet need for patients with PROC and help learners understand the opportunities and best treatment practices.   Faculty will outline and share the most up to date information on antibody drug conjugates (ADCs) by describing and sharing important details such as payloads, linkers and targets.  Finally, expert faculty will discuss a real-world scenario to share treatment challenges and benefits in recurrent disease.

This symposium was developed by Immunogen, Inc.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

    • Understand the unmet need in platinum resistant ovarian cancers and learn about the current treatment approaches for your patient.
    • Review antibody drug conjugates that may become available  in the EU to understand current and future treatment landscape and learn about the mechanism of action.
    • Discuss and engage with expert faculty on a real-world treatment scenario.

Moderator


Isabelle Ray-Coquard, MD, PhD

Faculty


Kathleen Moore, MD

Toon Van Gorp, MD, PhD

Agenda

The Integration of ADCs: Understanding The Advancing Treatment of PROC, an Industry Supported Symposium at the ESGO 2024 Congress

Friday, March 8, 2024 from 12:00 pm – 1:00 pm Local Barcelona Time.

Register Today

12:00 pm – 12:04 pm
Welcome & Introduction
All Faculty
12:04 pm – 12:16 pm
Understanding Current Treatment Approaches in Platinum Resistant Ovarian Cancer
Isabelle Ray-Coquard, MD, PhD, Centre Leon Berard, Lyon, France
12:16 pm – 12:28 pm
Are all ADCs Built The Same? Understanding The Science of Payloads, Linkers and Targets.
Kathleen Moore, MD, MS, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma, USA
12:28 pm – 12:40 pm
Clinical trial date with Mirvetuximab
Toon Van Gorp, MD, PhD, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium
12:40 pm – 1:00 pm
Panel Discussion, Audience Q&A
All Faculty